A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia

被引：2

作者：

Bazinet, Alexandre ^{[1
]}

Bataller, Alex ^{[1
]}

Kadia, Tapan ^{[1
]}

Daver, Naval ^{[1
]}

Short, Nicholas J. ^{[1
]}

Yilmaz, Musa ^{[1
]}

Sasaki, Koji ^{[1
]}

Dinardo, Courtney D. ^{[1
]}

Borthakur, Gautam M. ^{[1
]}

Issa, Ghayas ^{[1
]}

Bouligny, Ian ^{[1
]}

Pierce, Sherry ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Ravandi, Farhad ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

来源：

CANCER | 2025年 / 131卷 / 06期

关键词：

acute myeloid leukemia; FMS-like tyrosine kinase 3 (FLT3); FLT3; inhibitors; venetoclax; ADULT PATIENTS; FLT3; MUTATIONS; AML; CYTARABINE; YOUNGER; IMPACT;

D O I：

10.1002/cncr.35813

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: FMS-like tyrosine kinase 3 (FLT3) mutations, either internal tandem duplications (FLT3-ITD) or tyrosine kinase domain (FLT3-TKD), are common in acute myeloid leukemia (AML). FLT3-ITD confers an adverse prognosis. Methods: The authors performed a retrospective study including 619 patients to evaluate outcomes in newly diagnosed FLT3-mutated AML across treatment regimens. Results: In patients with FLT3-ITD-mutated AML who received intensive chemotherapy (IC), the addition of a FLT3 inhibitor (FLT3i) was associated with trends toward improved relapse-free survival (median 32.3 vs. 14.3 months with vs. without a FLT3i; p = .055) and overall survival (OS; 35.5 vs. 18.9 months with vs. without a FLT3i; p = .098). In patients with FLT3-ITD mutations who received low-intensity (LIT) regimens, triplets (LIT plus a FLT3i plus venetoclax) were associated with significantly longer OS (19.1 months) compared with those who received other treatment combinations (11.2 months with LIT alone, 9.2 months with LIT plus FLT3i, and 10.3 months with LIT plus venetoclax). Patients with FLT3-ITD plus NPM1 co-mutations who received any therapy had a trend toward improved OS (2-year OS: 47% vs. 33%; p = .087). The FLT3-ITD allelic ratio; IDH1, IDH2, WT1, RUNX1, and myelodysplastic syndrome-related mutations; and adverse cytogenetics had no significant impact on OS. In landmark analyses, allogeneic stem cell transplantation was associated with a trend toward improved OS in patients with FLT3-ITD mutations who received IC (52.6 vs. 22.7 months with versus without allogeneic stem cell transplantation; p = .076) and a marked improvement in OS in those who received LIT (38.6 vs. 14.0 months with vs. without allogeneic stem cell transplantation; p < .0001). Conclusions: A FLT3i and allogeneic stem cell transplantation are key treatment modalities for patients who have FLT3-mutated AML. LIT-based triplets are promising in IC-ineligible patients.

引用

页数：13

共 31 条

[1] Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab [J].

Abaza, Yasmin ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo ;

Estey, Elihu ;

Borthakur, Gautam ;

Jabbour, Elias ;

Faderl, Stefan ;

O'Brien, Susan ;

Wierda, William ;

Pierce, Sherry ;

Brandt, Mark ;

Mccue, Deborah ;

Luthra, Rajyalakshmi ;

Patel, Keyur ;

Kornblau, Steven ;

Kadia, Tapan ;

Daver, Naval ;

DiNardo, Courtney ;

Jain, Nitin ;

Verstovsek, Srdan ;

Ferrajoli, Alessandra ;

Andreeff, Michael ;

Konopleva, Marina ;

Estrov, Zeev ;

Foudray, Maria ;

Mccue, David ;

Cortes, Jorge ;

Ravandi, Farhad .

BLOOD, 2017, 129 (10) :1275-1283

[2] Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients [J].

Bacher, Ulrike ;

Haferlach, Claudia ;

Kern, Wolfgang ;

Haferlach, Torsten ;

Schnittger, Susanne .

BLOOD, 2008, 111 (05) :2527-2537

[3] Moving toward individualized target-based therapies in acute myeloid leukemia [J].

Bazinet, A. ;

Kantarjian, H. M. .

ANNALS OF ONCOLOGY, 2023, 34 (02) :141-151

[4] Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida) [J].

Borthakur, Gautam M. ;

Cortes, Jorge E. ;

Ravandi, Farhad ;

Garcia-Manero, Guillermo ;

Kadia, Tapan M. ;

Jabbour, Elias ;

Patel, Keyur ;

Issa, Ghayas C. ;

Daver, Naval G. ;

Ohanian, Maro N. ;

Brandt, Mark ;

Kantarjian, Hagop M. .

BLOOD, 2019, 134

[5] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia [J].

Daver, Naval ;

Perl, Alexander E. ;

Maly, Joseph ;

Levis, Mark ;

Ritchie, Ellen ;

Litzow, Mark ;

McCloskey, James ;

Smith, Catherine C. ;

Schiller, Gary ;

Bradley, Terrence ;

Tiu, Ramon, V ;

Naqvi, Kiran ;

Dail, Monique ;

Brackman, Deanna ;

Siddani, Satya ;

Wang, Jing ;

Chyla, Brenda ;

Lee, Paul ;

Altman, Jessica K. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) :4048-+

[6] Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML [J].

DiNardo, C. D. ;

Tiong, I. S. ;

Quaglieri, A. ;

MacRaild, S. ;

Loghavi, S. ;

Brown, F. C. ;

Thijssen, R. ;

Pomilio, G. ;

Ivey, A. ;

Salmon, J. M. ;

Glytsou, C. ;

Fleming, S. A. ;

Zhang, Q. ;

Ma, H. ;

Patel, K. P. ;

Kornblau, S. M. ;

Xu, Z. ;

Chua, C. C. ;

Chen, Xufeng ;

Blombery, P. ;

Flensburg, C. ;

Cummings, N. ;

Aifantis, I. ;

Kantarjian, H. ;

Huang, D. C. S. ;

Roberts, A. W. ;

Majewski, I. J. ;

Konopleva, M. ;

Wei, A. H. .

BLOOD, 2020, 135 (11) :791-803

[7] Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN [J].

Doehner, Hartmut ;

Wei, Andrew H. ;

Appelbaum, Frederick R. ;

Craddock, Charles ;

DiNardo, Courtney D. ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Godley, Lucy A. ;

Hasserjian, Robert P. ;

Larson, Richard A. ;

Levine, Ross L. ;

Miyazaki, Yasushi ;

Niederwieser, Dietger ;

Ossenkoppele, Gert ;

Roellig, Christoph ;

Sierra, Jorge ;

Stein, Eytan M. ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wang, Jianxiang ;

Wierzbowska, Agnieszka ;

Lowenberg, Bob .

BLOOD, 2022, 140 (12) :1345-1377

[8] Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, doubleblind, placebo-controlled, phase 3 trial [J].

Erba, Harry P. ;

Montesinos, Pau ;

Kim, Hee-Je ;

Patkowska, Elzbieta ;

Vrhovac, Radovan ;

Zak, Pavel ;

Wang, Po -Nan ;

Mitov, Tsvetomir ;

Hanyok, James ;

Kamel, Yasser Mostafa ;

Rohrbach, Jaime E. Connolly ;

Liu, Li ;

Benzohra, Aziz ;

Lesegretain, Arnaud ;

Cortes, Jorge ;

Perl, Alexander E. ;

Sekeres, Mikkael A. ;

Dombret, Herve ;

Amadori, Sergio ;

Wang, Jianxiang ;

Levis, Mark J. ;

Schlenk, Richard F. .

LANCET, 2023, 401 (10388) :1571-1583

[9] Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles [J].

Froehling, Stefan ;

Scholl, Claudia ;

Levine, Ross L. ;

Loriaux, Marc ;

Boggon, Titus J. ;

Bernard, Olivier A. ;

Berger, Roland ;

Doehner, Hartmut ;

Doehner, Konstanze ;

Ebert, Benjamin L. ;

Teckie, Sewit ;

Golub, Todd R. ;

Jiang, Jingrui ;

Schittenhelm, Marcus M. ;

Lee, Benjamin H. ;

Griffin, James D. ;

Stone, Richard M. ;

Heinrich, Michael C. ;

Deininger, Michael W. ;

Druker, Brian J. ;

Gilliland, D. Gary .

CANCER CELL, 2007, 12 (06) :501-513

[10] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].

Fröhling, S ;

Schlenk, RF ;

Breitruck, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

BLOOD, 2002, 100 (13) :4372-4380

← 1 2 3 4 →